Categories of risks in patients with type 1 or type 2 diabetes who fast during Ramadan
| Very high risk |
| Severe hypoglycemia within the last 3 months prior to Ramadan |
| Patient with a history of recurrent hypoglycemia |
| Patients with hypoglycemia unawareness |
| Patients with sustained poor glycemic control |
| Ketoacidosis within the last 3 months prior to Ramadan |
| Type 1 diabetes |
| Acute illness |
| Hyperosmolar hyperglycemic coma within the previous 3 months |
| Patients who perform intense physical labor |
| Pregnancy |
| Patients on chronic dialysis |
| High risk |
| Patients with moderate hyperglycemia (average blood glucose between 150 and 300 mg/dl, A1C 7.5–9.0%) |
| Patients with renal insufficiency |
| Patients with advanced macrovascular complications |
| People living alone that are treated with insulin or sulfonylureas |
| Patients living alone |
| Patients with comorbid conditions that present additional risk factors |
| Old age with ill health |
| Drugs that may affect mentation |
| Moderate risk |
| Well-controlled patients treated with short-acting insulin secretagogues such as repaglinide or nateglinide |
| Low risk |
| Well-controlled patients treated with diet alone, metformin, or a thiazolidinedione who are otherwise healthy |
| Very high risk |
| Severe hypoglycemia within the last 3 months prior to Ramadan |
| Patient with a history of recurrent hypoglycemia |
| Patients with hypoglycemia unawareness |
| Patients with sustained poor glycemic control |
| Ketoacidosis within the last 3 months prior to Ramadan |
| Type 1 diabetes |
| Acute illness |
| Hyperosmolar hyperglycemic coma within the previous 3 months |
| Patients who perform intense physical labor |
| Pregnancy |
| Patients on chronic dialysis |
| High risk |
| Patients with moderate hyperglycemia (average blood glucose between 150 and 300 mg/dl, A1C 7.5–9.0%) |
| Patients with renal insufficiency |
| Patients with advanced macrovascular complications |
| People living alone that are treated with insulin or sulfonylureas |
| Patients living alone |
| Patients with comorbid conditions that present additional risk factors |
| Old age with ill health |
| Drugs that may affect mentation |
| Moderate risk |
| Well-controlled patients treated with short-acting insulin secretagogues such as repaglinide or nateglinide |
| Low risk |
| Well-controlled patients treated with diet alone, metformin, or a thiazolidinedione who are otherwise healthy |